Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Zhang, Yu Wen ^a   Staal, Ben ^a   Dykema, Karl J ^a   Furge, Kyle A ^a   Vande Woude, George F ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; TRICHOSTATIN A; AZACITIDINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LUCIFERASE; MIG 6 PROTEIN, HUMAN; MIG-6 PROTEIN, HUMAN; PRIMER DNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; EPIGENETICS; EXON; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA; MICROARRAY ANALYSIS; MIG 6 GENE; MITOGEN INDUCIBLE GENE 6; NEGATIVE FEEDBACK; PROMOTER REGION; PROTEIN BINDING; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; TUMOR GENE; TUMOR SUPPRESSOR GENE; CPG ISLAND; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PLASMID; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AZACITIDINE; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CPG ISLANDS; DNA MODIFICATION METHYLASES; DNA PRIMERS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUCIFERASES; MICROARRAY ANALYSIS; MOLECULAR SEQUENCE DATA; PLASMIDS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 84862216069     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038955     Document Type: Article

References (34)

1. Zhang YW, Vande Woude GF, (2007) Mig-6, signal transduction, stress response and cancer. Cell Cycle 6: 507-513.
2. Makkinje A, Quinn DA, Chen A, Cadilla CL, Force T, et al. (2000) Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 275: 17838-17847.
3. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, et al. (2006) Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12: 568-573.
4. Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, et al. (2009) Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development 136: 3347-3356.
5. Zhang YW, Su Y, Lanning N, Swiatek PJ, Bronson RT, et al. (2005) Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A 102: 11740-11745.
6. Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, et al. (2003) Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22: 4221-4234.
7. Zhang X, Pickin KA, Bose R, Jura N, Cole PA, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450: 741-744.
8. Frosi Y, Anastasi S, Ballaro C, Varsano G, Castellani L, et al. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol 189: 557-571.
9. Hackel PO, Gishizky M, Ullrich A, et al. (2001) Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem 382: 1649-1662.
10. Pante G, Thompson J, Lamballe F, Iwata T, Ferby I, (2005) Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth. J Cell Biol 171: 337-348.
11. Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, et al. (2007) Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 26: 269-276.
12. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD, (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 60: 4894-4906.
13. Nomoto S, Haruki N, Tatematsu Y, Konishi H, Mitsudomi T, et al. (2000) Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer 28: 342-346.
14. Tseng RC, Chang JW, Hsien FJ, Chang YH, Hsiao CF, et al. (2005) Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 117: 241-247.
15. Poetsch M, Woenckhaus C, Dittberner T, Pambor M, Lorenz G, et al. (1999) Significance of the small subtelomeric area of chromosome 1 (1p36.3) in the progression of malignant melanoma: FISH deletion screening with YAC DNA probes. Virchows Arch 435: 105-111.
16. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, et al. (2005) Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24: 4540-4548.
17. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, et al. (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64: 844-856.
18. Caren H, Fransson S, Ejeskar K, Kogner P, Martinsson T, (2007) Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer 97: 1416-1424.
19. Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, et al. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 1: 265-277.
20. Jeong JW, Lee HS, Lee KY, White LD, Broaddus RR, et al. (2009) Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A 106: 8677-8682.
21. Li Z, Dong Q, Wang Y, Qu L, Qiu X, et al. (2011) Downregulation of Mig-6 in nonsmall-cell lung cancer is associated with EGFR signaling. Mol Carcinog.
22. Lin CI, Du J, Shen WT, Whang EE, Donner DB, et al. (2011) Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab 96: E554-565.
23. Reschke M, Ferby I, Stepniak E, Seitzer N, Horst D, et al. (2010) Mitogen-inducible gene-6 is a negative regulator of epidermal growth factor receptor signaling in hepatocytes and human hepatocellular carcinoma. Hepatology 51: 1383-1390.
24. Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, et al. (2008) Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery 144: 908-913; discussion 913-904.
25. Jones PA, Baylin SB, (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
26. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, et al. (2005) Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and-independent mechanisms. Leukemia 19: 103-111.
27. Mai A, Altucci L, (2009) Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 41: 199-213.
28. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, et al. (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 212: 330-344.
29. Yoo CB, Jones PA, (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
30. Taddei A, Roche D, Bickmore WA, Almouzni G, (2005) The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 6: 520-524.
31. Hilger-Eversheim K, Moser M, Schorle H, Buettner R, (2000) Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 260: 1-12.
32. Orso F, Cora D, Ubezio B, Provero P, Caselle M, et al. (2010) Identification of functional TFAP2A and SP1 binding sites in new TFAP2A-modulated genes. BMC Genomics 11: 355.
33. Thiel G, Cibelli G, (2002) Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193: 287-292.
34. VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL, (2009) Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res 69: 1985-1994.